메뉴 건너뛰기




Volumn 35, Issue 5, 2012, Pages 417-427

A cohort study exploring determinants of safety-related regulatory actions for biopharmaceuticals

Author keywords

Pharmacovigilance; Regulatory processes.

Indexed keywords

BIOPHARMACEUTICAL AGENT; PHARMACEUTICAL VEHICLES AND ADDITIVES; UNCLASSIFIED DRUG;

EID: 84859810212     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11597850-000000000-00000     Document Type: Article
Times cited : (5)

References (30)
  • 1
    • 0036598634 scopus 로고    scopus 로고
    • Bioequivalence and the immunogenicity of biopharmaceuticals
    • Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals.NatRevDrugDiscov 2002; 1 (6): 457-62
    • (2002) Nat Rev Drug Discov , vol.1 , Issue.6 , pp. 457-462
    • Schellekens, H.1
  • 2
    • 33644865904 scopus 로고    scopus 로고
    • Early development of therapeutic biologicspharmacokinetics
    • Baumann A. Early development of therapeutic biologicspharmacokinetics. Curr Drug Metab 2006; 7 (1): 15-21
    • (2006) Curr Drug Metab , vol.7 , Issue.1 , pp. 15-21
    • Baumann, A.1
  • 3
    • 77956334120 scopus 로고    scopus 로고
    • Mapping the safety profile of biologicals: A disproportionality analysis using the WHO adverse drug reaction database VigiBase
    • Giezen TJ, Mantel-Teeuwisse AK, Meyboom RH, et al. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Drug Saf 2010; 33 (10): 865-78
    • Drug Saf 2010 , vol.33 , Issue.10 , pp. 865-878
    • Giezen, T.J.1    Mantel-Teeuwisse, A.K.2    Meyboom, R.H.3
  • 4
    • 33745786806 scopus 로고    scopus 로고
    • Adverse side-effects to biological agents
    • Pichler WJ. Adverse side-effects to biological agents. Allergy 2006; 61 (8): 912-20
    • (2006) Allergy , vol.61 , Issue.8 , pp. 912-920
    • Pichler, W.J.1
  • 5
    • 70449709036 scopus 로고    scopus 로고
    • Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval
    • Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval. Drug Saf 2009; 32 (12): 1175-87
    • (2009) Drug Saf , vol.32 , Issue.12 , pp. 1175-1187
    • Giezen, T.J.1    Mantel-Teeuwisse, A.K.2    Straus, S.M.3
  • 6
    • 54349091558 scopus 로고    scopus 로고
    • Safetyrelated regulatory actions for biologicals approved in the United States and the European Union
    • Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Safetyrelated regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008; 300 (16): 1887-96
    • (2008) JAMA , vol.300 , Issue.16 , pp. 1887-1896
    • Giezen, T.J.1    Mantel-Teeuwisse, A.K.2    Straus, S.M.3
  • 7
    • 77952855654 scopus 로고    scopus 로고
    • A decade of safetyrelated regulatory action in the Netherlands: A retrospective analysis of direct healthcare professional communications from 1999 to 2
    • Mol PG, Straus SM, Piening S, et al. A decade of safetyrelated regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2 Drug Saf 2010; 33 (6): 463-74
    • (2010) Drug Saf , vol.33 , Issue.6 , pp. 463-474
    • Mol, P.G.1    Straus, S.M.2    Piening, S.3
  • 8
    • 79751511440 scopus 로고    scopus 로고
    • European Medicines Agency [online] [Accessed 2011 Aug 2]
    • European Medicines Agency (2008). Volume 9A of The Rules Governing Medicinal Products in the European Union [online]. Available from URL: http://ec.europa.eu/en terprise/pharmaceuticals/eudralex/vol-9/pdf/vol9a-09- 2008.pdf [Accessed 2011 Aug 2]
    • (2008) Volume 9A of the Rules Governing Medicinal Products in the European Union
  • 9
    • 0030787821 scopus 로고    scopus 로고
    • Principles of signal detection in pharmacovigilance
    • Meyboom RH, Egberts AC, Edwards IR, et al. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16 (6): 355-65
    • (1997) Drug Saf , vol.16 , Issue.6 , pp. 355-365
    • Meyboom, R.H.1    Egberts, A.C.2    Edwards, I.R.3
  • 10
    • 0035038538 scopus 로고    scopus 로고
    • The use of evidence in pharmacovigilance: Case reports as the reference source for drug withdrawals
    • Arnaiz JA, Carne X, Riba N, et al. The use of evidence in pharmacovigilance: case reports as the reference source for drug withdrawals. Eur J Clin Pharmacol 2001; 57 (1): 89-91
    • (2001) Eur J Clin Pharmacol , vol.57 , Issue.1 , pp. 89-91
    • Arnaiz, J.A.1    Carne, X.2    Riba, N.3
  • 11
    • 0036570099 scopus 로고    scopus 로고
    • Timing of new black box warnings and withdrawals for prescription medications
    • Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287 (17): 2215-20
    • (2002) JAMA , vol.287 , Issue.17 , pp. 2215-2220
    • Lasser, K.E.1    Allen, P.D.2    Woolhandler, S.J.3
  • 12
    • 32244432294 scopus 로고    scopus 로고
    • An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets
    • Clarke A, Deeks JJ, Shakir SA. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf 2006; 29 (2): 175-81
    • (2006) Drug Saf , vol.29 , Issue.2 , pp. 175-181
    • Clarke, A.1    Deeks, J.J.2    Shakir, S.A.3
  • 13
    • 33751071330 scopus 로고    scopus 로고
    • The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France
    • Olivier P, Montastruc JL. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Pharmacoepidemiol Drug Saf 2006; 15 (11): 808-12
    • (2006) Pharmacoepidemiol Drug Saf , vol.15 , Issue.11 , pp. 808-812
    • Olivier, P.1    Montastruc, J.L.2
  • 14
    • 37249007168 scopus 로고    scopus 로고
    • European Medicines Agency [online] [Accessed 2011 Jul 12]
    • European Medicines Agency. EPARs for authorised medicinal products for human use [online]. Available from URL: http://www.ema.europa.eu/htms/human/ epar/a.htm. [Accessed 2011 Jul 12]
    • EPARs for Authorised Medicinal Products for Human Use
  • 15
    • 84968762251 scopus 로고    scopus 로고
    • European Commission [online] [Accessed 2011 Aug 2]
    • European Commission. The Community Register of medicinal products [online]. Available from URL: http://ec. europa.eu/enterprise/sectors/ pharmaceuticals/documents/ community-register/index-en.htm [Accessed 2011 Aug 2]
    • The Community Register of Medicinal Products
  • 16
    • 84859819874 scopus 로고    scopus 로고
    • WHO Collaborating Centre for Drug Statistics Methodology 18-06-2011
    • WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2 10-05-2011; 18-06-2011
    • ATC/DDD Index 2 10-05-2011
  • 17
    • 33748675101 scopus 로고    scopus 로고
    • European Commission (revision 2) [online] [Accessed 2011 Aug 2]
    • European Commission (2009). A guideline on summary of product characteristics (revision 2) [online]. Available from URL: http://ec.europa.eu/ health/files/eudralex/vol-2/c/smpc-guideline-rev2-en.pdf [Accessed 2011 Aug 2]
    • (2009) A Guideline on Summary of Product Characteristics
  • 18
    • 84859838574 scopus 로고    scopus 로고
    • Commission regulation (EC) No 1234/2
    • European Commission 12/12/2008 [online] [Accessed 2011 Aug 2]
    • European Commission (2008). Commission regulation (EC) No 1234/2 Official Journal L 334, 12/12/2008, pp. 7-24 [online] Available from URL: http://ec.europa.eu/health/ files/eudralex/vol-1/reg-2008-1234/reg-2008-1234-en. pdf [Accessed 2011 Aug 2]
    • (2008) Official Journal L , vol.334 , pp. 7-24
  • 19
    • 77955551374 scopus 로고    scopus 로고
    • Risk management plans: Are they a tool for improving drug safety?
    • Frau S, Font Pous M, Luppino MR, et al. Risk management plans: are they a tool for improving drug safety? Eur J Clin Pharmacol 2010; 66 (8): 785-90
    • (2010) Eur J Clin Pharmacol , vol.66 , Issue.8 , pp. 785-790
    • Frau, S.1    Font Pous, M.2    Luppino, M.R.3
  • 20
    • 67449144386 scopus 로고    scopus 로고
    • European biologicals registers: Methodology, selected results and perspectives
    • Zink A, Askling J, Dixon WG, et al. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009; 68 (8): 1240-6
    • (2009) Ann Rheum Dis , vol.68 , Issue.8 , pp. 1240-1246
    • Zink, A.1    Askling, J.2    Dixon, W.G.3
  • 21
    • 0036593951 scopus 로고    scopus 로고
    • Preclinical safety evaluation of biotechnology- derived pharmaceuticals
    • Cavagnaro JA. Preclinical safety evaluation of biotechnology- derived pharmaceuticals. Nat Rev Drug Discov 2002; 1 (6): 469-75
    • (2002) Nat Rev Drug Discov , vol.1 , Issue.6 , pp. 469-475
    • Cavagnaro, J.A.1
  • 22
    • 77952819564 scopus 로고    scopus 로고
    • Validation of statistical signal detection procedures in eudravigilance post-authorization data: A retrospective evaluation of the potential for earlier signaling
    • Alvarez Y, Hidalgo A, Maignen F, et al. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. Drug Saf 2010; 33 (6): 475-87
    • (2010) Drug Saf , vol.33 , Issue.6 , pp. 475-487
    • Alvarez, Y.1    Hidalgo, A.2    Maignen, F.3
  • 23
    • 57949092897 scopus 로고    scopus 로고
    • The politics and bio-ethics of regulatory trust: Case-studies of pharmaceuticals
    • Abraham J. The politics and bio-ethics of regulatory trust: case-studies of pharmaceuticals. Med Health Care Philos 2008; 11 (4): 415-26
    • (2008) Med Health Care Philos , vol.11 , Issue.4 , pp. 415-426
    • Abraham, J.1
  • 24
    • 84881264406 scopus 로고    scopus 로고
    • Europes opportunity to open up drug regulation
    • Garattini S, Bertele V. Europes opportunity to open up drug regulation. BMJ 2010; 340: c1578
    • BMJ , vol.2010 , Issue.340
    • Garattini, S.1    Bertele, V.2
  • 25
    • 84859876801 scopus 로고    scopus 로고
    • The FDA and the black arts of drug regulation
    • Rawlins M. The FDA and the black arts of drug regulation. Lancet 2010; 376 (9751): 1455-6
    • (2010) Lancet , vol.376 , Issue.9751 , pp. 1455-1456
    • Rawlins, M.1
  • 26
    • 77951074523 scopus 로고    scopus 로고
    • Improving pharmacovigilance in Europe
    • MooreN, Begaud B. Improving pharmacovigilance in Europe. BMJ 2010; 340: c1694
    • (2010) BMJ , vol.340
    • Moore, N.1    Begaud, B.2
  • 27
    • 77958008305 scopus 로고    scopus 로고
    • Evaluation of benefit-risk
    • Garattini S. Evaluation of benefit-risk. Pharmacoeconomics 2010; 28 (11): 981-6
    • (2010) Pharmacoeconomics , vol.28 , Issue.11 , pp. 981-986
    • Garattini, S.1
  • 29
    • 78049521348 scopus 로고    scopus 로고
    • Using market-exclusivity incentives to promote pharmaceutical innovation
    • Kesselheim AS. Using market-exclusivity incentives to promote pharmaceutical innovation. N Engl J Med 2010; 363 (19): 1855-62
    • (2010) N Engl J Med , vol.363 , Issue.19 , pp. 1855-1862
    • Kesselheim, A.S.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.